Spironolactone for Paroxysmal Atrial Fibrillation

Taichung Veterans General Hospital

Status: Unknown

Conditions: Atrial Fibrillation

Treatments: Drug: Placebo; Drug: Spironolactone

Study type: Interventional

Funder types: Other

Identifiers

NCT00689598

C07061

Details and patient eligibility

About

To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.

Full description

To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. 18 to 80 Y/O,
2. Paroxysmal AF.

Exclusion criteria

1. GPT>100 IU/L or tota bilirubin >2 mg/dl;
2. Creatinine > 2 mg/dl;
3. Serum potassium >= 5 mM;
4. Serum sodium <=130 mM;
5. Uric acid > 10 mg/dl。

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 2 patient groups, including a placebo group

III

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Spironolactone

Experimental

Experimental group

Description:

Drug intervention

Treatment:

Drug: Spironolactone

Drug: Placebo